drugset / Trial / NCT06756035
CT-95 in Advanced Cancers Associated With Mesothelin Expression
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.
Timeline
- Start
- 2025-03-31
- Primary completion
- 2026-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT-95 | Monoclonal antibody | — | Intravenous |